LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and ...

Former Takeda CSO and a16z Bio + Health Founder to Guide Clinical Translation and Scaling of insitro’s ChemML™ Platform insitro, the AI therapeutics company built on causal biology, today announced ...

CRISPR Therapeutics (CRSP) earns a Hold rating as pipeline breadth grows but CASGEVY's launch remains slow and economically unattractive. CRSP’s in vivo editing platform shows strong early validation, ...

Intellia Therapeutics, Inc. is rated Hold due to safety concerns after a patient death in its Phase 3 MAGNITUDE trial for ATTR-CM. NTLA's CRISPR/Cas9 gene editing offers potentially best-in-class, one ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...

Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs. Wall Street may be pricing in too ...

UpSMART, a research programme involving 24 European cancer centres, aimed to promote digital innovation in early-phase clinical research addressing challenges in recruitment, data collection and ...